Impact of Cytomegalovirus Infection on Outcomes of Allogeneic Haematopoietic Cell Transplantation
Report of data presented at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation, 2017.
Click here to read the full report.
AGA: IBD in Pregnancy Clinical Care Pathway
Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report from the American Gastroenterological Association IBD Parenthood Project Working Group
Click here to read the full article
Poster: Enhancing Awareness and Understanding of Gene Therapy Among Rare Disease Communities: A Research-driven Roadmap
Poster presented at Gene Therapy for Rare Diseases conference, New York Academy of Sciences, New York, N.Y., Apr. 11, 2017
Click here to view the poster
A profile of Piramal Imaging, a division of Piramal Enterprises Ltd., a global radiopharmaceutical company developing novel PET radiotracers for use in molecular imaging.
Click here to read the full article.
COURSE OBJECTIVE: The purpose of this course is to provide the healthcare professional with a review of metabolic syndrome, including measurements, laboratory tests, causes, potential consequences, and preventive measures.
Upon completion of this course, you will be able to:
Define metabolic syndrome.
Identify two key findings on physical examination that indicate possible metabolic syndrome.
Name three laboratory values that indicate possible metabolic syndrome.
Define insulin resistance.
Discuss the two most serious consequences of developing metabolic syndrome.
Describe two major lifestyle changes that can help treat and prevent metabolic syndrome.
Metabolic syndrome is the name for a particular cluster of health problems first identified in 1988 by Gerald Reaven, a Stanford University endocrinologist, in a lecture to the American Diabetes Association (Reaven et al., 2000). At various times, this syndrome has been called dysmetabolic syndrome, insulin resistance syndrome, obesity dyslipidemia syndrome, and syndrome X. (Now simply known as metabolic syndrome, the “X” […]
Menstrually Related Migraine Treatments
An overview of the efficacy of several triptan agents in menstrually related migraine (MM), as well as of other treatment modalities that are commonly used in the treatment of MM.
Steven D. Silberstein, MD, FACP
Practical Pain Management, May-June 2002
Many researchers have established a link between estrogen and progesterone — the female sex hormones — and migraine.[1-5] Migraine occurs more frequently in adult women (18%) than in men (6%),[2,6] and develops most frequently in the second decade, with the peak incidence occurring with adolescence.[1-4] Menstrually related migraine (MM) begins at menarche in 33% of affected women, occurring mainly at the time of menses in many migrainous women and exclusively with menses — true menstrual migraine (TMM) — in some. Its frequency has been reported to be as high as 60% to 70%; retrospective analysis suggests that its prevalence ranges from 26% to 60%, in headache clinic […]
Cardiovascular Disease in Chronic Kidney Disease: Emphasis on Left Ventricular Hypertrophy
Guruprasad Manjunath, MD; Andrew S. Levey, MD; Mark J. Sarnak, MD
From the Division of Nephrology, Department of Medicine, New England Medical Center, Boston, MA
Abstract: Cardiovascular disease is the leading cause of morbidity and mortality in patients with chronic kidney disease. The prevalence of cardiovascular disease is high among patients starting dialysis therapy, indicating that cardiovascular disease begins when the glomerular filtration rate declines—the stage preceding end-stage renal disease. Left ventricular hypertrophy is one of the major risk factors for cardiovascular disease morbidity and mortality in end-stage renal disease and has an extremely high prevalence in chronic kidney disease. Hypertension and anemia are two of the major modifiable risk factors for the development of left ventricular hypertrophy. Treatment of hypertension, particularly with the use of angiotensin-converting enzyme inhibitors, and anemia management with recombinant human erythropoietin, may result in regression of left ventricular hypertrophy and thereby […]
Mesalamine Induces Mucosal Healing In Ulcerative Colitis
David T. Rubin, MD
Assistant Professor of Medicine
Section of Gastroenterology
The University of Chicago
Abstract: Whereas treatment of ulcerative colitis (UC) largely focuses on relieving the symptoms of rectal bleeding and frequent stools, many pathologists and gastroenterologists believe that mucosal healing is an important aspect of the treatment process. There is evidence that the degree of mucosal inflammation may have relevance for future disease risk, and may correlate with disease remission rates and long-term outcomes. Numerous studies suggest that treatment with mesalamine can induce mucosal healing, possibly resulting in durable remission of UC. Recent data demonstrate that mesalamine therapy results in endoscopically measured mucosal healing as early as 3 weeks, with mucosal healing evident throughout the colon, while also improving rectal bleeding and stool frequency regardless of the location or extent of UC. Those findings suggest the predictive value of mucosal healing in treatment outcomes, a concept […]
Controversies in Diagnostic Imaging: Contrast-Induced Nephropathy
By: Stanley Goldfarb, MD, FACP, FASN, FCPP
In recent years, concerns about nephrotoxicity associated with high-osmolality contrast media (HOCM) have led to more widespread use of low- and iso-osmolality contrast agents in diagnostic imaging procedures. Those concerns have largely focused on contrast-induced nephropathy (CIN), the commonest and most important complication of the use of iodinated radiocontrast material. CIN has been variably defined as a condition characterized by kidney dysfunction following exposure to radioiodinated contrast media when no other explanation such as hypotension or sepsis can be implicated. The most common definition of CIN is a rise in serum creatinine (SCr) by 25% above baseline or an absolute increase of 0.5 mg/dl. However, recent observations have called into question the specificity of the diagnosis, as up to 20% of patients who are hospitalized with cardiac disease and who never receive contrast media may also have a […]
Reputation Management in the Biotechnology Industry
Robert W. Grupp and Leslie Gaines-Ross
Journal of Commercial Biotechnology, September 2002
Abstract: As biotechnology companies mature, the focus of their activities shifts from a research-and development orientation to a business model based on marketed products that deliver revenue and earnings. Companies are thus striving to occupy key positions at every stage of the industry’s evolving value chain, covering each step from gene identification to patient care. The management of corporate reputation must therefore be based on the new biotechnology business model, which takes into account the shifting industry value chain. The authors discuss how the function of corporate communications in biotechnology is changing along with the industry itself, as well as the key components of a biotechnology company’s reputation in the current environment. Additionally, a case study of Cephalon, Inc., is presented to illustrate how positive and negative events can affect corporate reputation in the […]